       Document 0580
 DOCN  M94A0580
 TI    Kaposi's sarcoma (K.S.): the Fairfield Hospital experience.
 DT    9412
 AU    Padiglione A; Goldstein D; Fairfield Hospital, Vic.
 SO    Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:96 (poster no. 42).
       Unique Identifier : AIDSLINE ASHM5/94349075
 AB    Kaposi's sarcoma is the most common malignancy occurring in patients
       with HIV infection, affecting about 21% of patients with AIDS, and is
       associated with significant morbidity and mortality. A number of
       therapeutic interventions are employed in the routine management of
       these patients, principally being alpha interferon, radiotherapy and
       cytotoxic chemotherapy. A survival benefit for chemotherapy has not yet
       been clearly demonstrated. In this study, we retrospectively analysed
       the effect of chemotherapy on the natural history of K.S., by analysing
       the case records of over 30 patients with K.S. treated with between 1988
       and 1992, and comparing these with matched controls of patients with
       untreated K.S. We also analysed the effect on survival of having K.S. as
       the AIDS defining illness.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY  Human
       Retrospective Studies  Sarcoma, Kaposi's/*DRUG THERAPY/MORTALITY  Skin
       Neoplasms/*DRUG THERAPY/MORTALITY  Survival Analysis  Victoria  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

